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Maker (insightmaker.com), simulated a 33-bed ward. Patients were assumed to move 
between five states: susceptible, susceptible and vulnerable due to antimicrobial 
use, colonised, colonised and vulnerable, or infected (symptomatic). Clinical inputs 
were identified from peer-reviewed primary research papers, systematic reviews, 
published models, data published by the NHS and from clinical experts. Relevant 
costs were identified from Department of Health guidelines on C.diff infection man-
agement and other published sources, and inflated to 2014 values where necessary. 
We assumed that a fine of £10,000 per case was issued when evidence of hospital 
transmission was found, indicating that the infection was hospital-acquired; English 
hospitals are fined for hospital-acquired cases above an annual threshold, which 
varies between hospitals. Results: As a result of the low prevalence of C.diff, no 
outbreaks were observed over the one-year time horizon. There were 2.95 cases of 
C.diff in the base case, equivalent to 2.68 cases per 10,000 bed days. Fewer cases 
showed evidence of transmission when using WGS, which resulted in lower fines 
for the hospital (assuming a zero case tolerance policy). Annual C.diff-attributable 
costs for the ward were therefore £1,490 lower when WGS was used compared to 
ribotyping alone, although initial setup costs and service running costs were not 
included. ConClusions: This system dynamics model is the first formal attempt 
to evaluate the cost-effectiveness of WGS for monitoring connections between C.diff 
cases. Depending on the annual threshold for cases and the availability of WGS, 
initial results indicate that WGS may be cost-saving at a hospital level due to fewer 
cases being subject to a fine.
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Costs anD ConsequenCes of Dialysis relateD infeCtions: 
iMPliCations for the bunDleD PayMents for Care iMProveMent 
initiative
Queeley G.L., Campbell E.S.
Florida A&M University, Tallahassee, FL, USA
objeCtives: Treatment for post dialysis infections imposes a significant eco-
nomic burden on the national health care system. The rate of hospitalization for 
bloodstream infections for Hemodialysis (HD) alone has increased 51 percent with 
an estimated cost in excess of $US 23,000 per hospitalization. The new bundled 
payments for care improvement (BPCI) initiative, promotes healthcare interven-
tions that improve patient outcomes at a lower cost. Peritoneal dialysis (PD) has 
been purported to lower the risk of bloodstream infections, which could poten-
tially reduce hospitalization costs. The purpose of this study was to estimate the 
cost per hospitalizations averted by substituting PD for HD. Methods: Data on 
treatment costs, and hospitalization rates for HD and PD were obtained from the 
USRDS registry. Using a payer perspective, a decision tree model was used to esti-
mate the ICER. Univariate sensitivity analysis was done to assess the robustness 
of the results. Results: Using PD was clearly cost-effective with an average cost 
of $50,320.08 per patient per year and resulted in 1,202 dialysis related hospitaliza-
tions; compared to HD which cost $69,916.28 per patient per year and resulted in 
1,462 dialysis-related hospitalizations. ConClusions: PD resulted in overall lower 
mean costs and hospitalization rates compared to HD. Considering the “payment 
for results” nature of the BPCI, PD has a high likelihood of being adopted as the 
preferred intervention in ESRD.
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a Cost-effeCtiveness analysis of bioMarker testing to target 
treatMent to Patients with MilD Cognitive iMPairMent at inCreaseD 
risk of alzheiMer’s Disease
Michaud T.L., Kuntz K.
University of Minnesota, Minneapolis, MN, USA
objeCtives: To quantify the potential value of cerebrospinal fluid (CSF) biomarker 
testing for patients with mild cognitive impairment (MCI). Biomarkers provide 
information about a patient’s risk of developing AD and can allow for early tar-
geted interventions for those patients found to be at higher risk of AD than oth-
ers. Methods: We developed a state-transition Markov model to project lifetime 
AD-free life years, costs and quality-adjusted life years (QALYs). We conducted a 
cost-effectiveness analysis of using CSF biomarker testing combined with the sub-
sequent treatments to delay the clinical diagnosis of AD (test-treat) compared to 
no treatment, and treatment strategies. For the test-treat strategies, we considered 
treating by different levels of risk, varying from treating only the highest risk group 
to treating all but the lowest risk group (total 5 risk levels). We performed deter-
ministic and probabilistic sensitivity analyses (PSA) and conducted an expected 
value of perfect information (EVPI) analysis to estimate the value of eliminating 
uncertainty of all parameters. Results: We found that treating MCI patients by 
their risk levels produced extra 0.9-3.8 AD-free life months compared to no treat-
ment. Three out of four test-treat strategies were ruled out by extended dominance. 
No treatment resulted in the highest cost and the highest effectiveness, with an 
incremental cost-effectiveness ratio of $30,000 per QALY compared to treating all 
patients. No treatment was optimal in 63% of the PSA iterations over 37% of the 
treatment strategy at willingness to pay of $50,000/QALY. The total EVPI was $3,512 
per patient. ConClusions: This study illustrates the potential for early targeted 
interventions for MCI patients who are at increased risk of developing AD. The 
design of this model and the findings could also be used to guide further research 
evaluating the cost-effectiveness of other biomarkers used to identify MCI patients 
at increased risk of progression to AD.
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objeCtives: Cardiac rhythm diseases related to syncope are of increasing incidence 
and prevalence worldwide including Colombia. Diagnosing transient arrhythmia 
is difficult with short term monitoring methods. We sought to compare cost-effec-
lished sources. The zero tolerance MRSA policy set by NHS England, which includes 
financial sanctions, was implemented in the model. Results: Over a one-year 
time horizon, although prevalence was higher on the high-risk ward, outbreaks 
occurred most frequently on the low-risk ward due to the higher number of patients. 
Preliminary results indicate that fewer outbreaks were declared when using WGS to 
identify the MRSA strain compared to current methods, due to the increased sensi-
tivity of WGS in identifying unrelated MRSA strains and therefore classifying fewer 
concurrent colonisations/infections as ‘outbreaks’. Fewer outbreaks resulted in cost-
savings due mainly to a lower cost of fines, and therefore WGS is likely to be cost-
effective where the technology and infrastructure is available. ConClusions: This 
newly developed model is the first formal attempt to evaluate the cost-effectiveness 
of WGS for detecting and monitoring outbreaks of MRSA. Initial results indicate that 
WGS will be cost-effective due to fewer outbreaks being declared. Further planned 
developments include expanding the model to simulate a complete hospital, as 
well as including start-up costs of setting up WGS services.
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Cost-effeCtiveness of aqP4 antiboDy DeteCtion with Cell-baseD 
assay CoMPareD with elisa for DeviC Disease Diagnosis in ColoMbia
Rosselli D.1, Acosta A.1, Castañeda C.1, Ruiz-Patiño A.2, Ruiz R.1
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objeCtives: Neuromyelitis optica (NMO) or Devic disease is a rare chronic condition 
characterized by demyelinating lesions in the central nervous system. The aim of 
this study was to evaluate cost-effectiveness of the detection of antibodies against 
the protein aquaporin water channel 4 (AQP4) with cell-based assay (CBA), compared 
with ELISA, for the diagnosis of NMO in Colombia. Methods: A decision tree model 
was constructed to compare costs, correctly diagnosed cases and relapses averted in 
patients with clinical suspicion of NMO, that were subjected to diagnostic tests for 
the detection of AQP4 antibodies. The analysis was undertaken from a third-party 
payer perspective, one year time horizon (first year with the disease) taking all 
costs for treatment and relapses, in 2014 Colombian pesos, from official published 
prices (1 USD = 2,033 COP). Since the CBA kit is not available in Colombia (currently 
samples are processed abroad), the price was obtained from the manufacturer and 
set in a national laboratory. Clinical variables were from a systematic literature 
review. Univariate and probabilistic sensitivity analyses (a Monte Carlo simulating a 
cohort of 1000 patients) were conducted. Results: Identification of AQP4 antibod-
ies with CBA is a dominant strategy: more effective (855 correctly diagnosed patients 
compared with 765 detected by ELISA, and 130 avoided relapses), and less costly, 
with expected yearly costs per correctly diagnosed Devic patient of USD $14,658 
compared with $15,614 for ELISA. Using CBA may represent savings in terms of 
reduced costs of treating disease and relapse with hospitalization. ConClusions: 
AQP4 antibody identification by the CBA method is a cost-saving diagnostic test, 
dominant over the ELISA method.
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objeCtives: Stroke is the most severe and debilitating consequence of atrial fibril-
lation (AF), with many patients ranking the resultant disability as worse than death. 
Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, 
but is associated with increased bleeding risk and lower quality of life (QoL). Left 
atrial appendage closure (LAAC) with the Watchman Device has been found to be 
superior to warfarin at reducing risk of stroke in AF patients. This analysis sought 
to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in 
non-valvular AF from the perspective of the US Centers for Medicare and Medicaid 
Services (CMS). Methods: A Markov model was constructed comparing clinical 
outcomes, QoL, and total costs of LAAC versus warfarin using PROTECT AF 4-year 
data. All clinical events reported in PROTECT AF were modeled over 1-year incre-
ments for 20 years to determine time to cost effectiveness. The model was populated 
with a cohort of 10,000 70-year old patients with a mean CHADS2 score of 2. Cost 
data were taken from 2015 US DRGs. One-way and probabilistic sensitivity analy-
ses were performed. Results: LAAC patients were estimated to live an additional 
1.1 quality-adjusted life years (QALYs) compared to warfarin patients. By year six, 
LAAC was cost effective in terms of QALYs ($40,221/QALY ) and life years gained 
($45,610/LYG). LAAC was dominant over warfarin at 10 years and remained so for 
the 20-year time horizon. The probability of cost effectiveness at 10 years was 99% 
given a willingness-to-pay threshold of $50,000 per QALY. ConClusions: LAAC 
with the Watchman Device is a cost effective alternative to warfarin therapy for 
stroke risk reduction in non-valvular AF. LAAC provides improved QOL, increased 
life expectancy, and offers better value to CMS over a patient’s lifetime.
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baCterial whole-genoMe sequenCing for Monitoring outbreaks of 
ClostriDiuM DiffiCile
Buchanan-Hughes A.M.1, Agirrezabal I.1, Eddowes L.A.1, Luheshi L.M.2, Török M.E.3, Sagoo G.S.2
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objeCtives: To develop a system dynamics model to analyse the cost-effective-
ness of bacterial whole-genome sequencing (WGS) versus current typing methods 
(ribotyping) alone in monitoring outbreaks of Clostridium difficile (C.diff) in the UK 
National Health Service (NHS). Methods: The model, constructed using Insight 
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obtained from Brazilian official price lists. Results: 95,688 hospitalizations were 
identified with total length of stay (LOS) of 336,939 days; deaths and mortality rates 
were 866 and 0.91 respectively.1 The model estimated costs for the inpatient period 
assuming one dressing change every 3 days for MEDIHONEY and AG, considering 
in both cases a similar size. Cost per dressing change was estimated as USD35.80 
and US31.85 for AG and MEDIHONEY, with mean healing time of 53 and 31 days, 
respectively.2 Overall treatment costs were USD4,020,805.30 and USD3,577,169.00 
according to the LOS and USD632.46 and USD329.12 according to MHT/patient for 
AG and MEDIHONEY, respectively. MEDIHONEY-related incremental costs were 
USD31,492,834 indicating a cost-saving proﬁle. Adopting MEDIHONEY as wound 
management protocol would save USD29,025,998 for the 2013/2014-cohort. Clinical 
benefits for use of MEDIHONEY CALCIUM ALGINATE over AG include decreased 
risk of hypersensitivity to compounds, MEDIHONEY treatment is appropriate 
throughout wound healing process and MEDIHONEY does not induce microbial 
resistance.3 ConClusions: MEDIHONEY dressing demonstrates cost-effectiveness 
when compared to AG dressings. These results reinforce the need for evidence-based 
decision making and rational resource allocation; in addition to further studies 
including clinical outcomes data.
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Cost effeCtiveness of saCral neurostiMulation for overaCtive 
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objeCtives: The objective is to develop a full economic evaluation of the cost 
effectiveness of using sacral neurostimulation versus botulinum toxin type A and 
augmentation cystoplasty in the treatment of overactive bladder in Mexico, from 
the perspective of the public health sector. Methods: A systematic literature 
review was conducted to identify articles to extract data on safety and efficacy of: 
sacral neurostimulation, botulinum toxin type A, and augmentation cystoplasty. 
A cost-effectiveness analysis was performed using a Markov model with a time 
horizon of 1 to 5 years. The effectiveness was measured as continence years and 
quality-adjusted life year (QALY). Only direct medical costs were considered, such 
as: medicine, surgery, devices, adverse events, days of hospitalization and labora-
tory studies; an analysis of incremental cost-effectiveness ratio (ICER) and incre-
mental cost-utility (ICU) was performed. To test the model and demonstrate the 
robustness, a probabilistic sensitivity analysis was performed, using Monte Carlo 
simulations. Results: Sacral neurostimulation showed better efficacy with 3.65 
continence years and 3.27 QALY’s with a cost of $279,538.11- The ICER over botuli-
num toxin A was 69,917.92, less than one time the Mexican GDP per capita, for the 
botulinum toxin the cost was 191,143.86 with 2.39 continence years and 2.13 QALY´s; 
for augmentation cystoplasty the cost was $205,049.02 with 3.19 continence years 
and 2.85 QALY’s. The probabilistic sensitivity analysis demonstrated that sacral 
neurostimulation is a cost-effective alternative, despite the modification of all the 
model’s variables. ConClusions: Sacral neurostimulation is a very cost-effective 
alternative for patients in the the public health care system in Mexico, being ICU 
and ICER less than one time the Mexican GDP per capita.
PMD45
CarDioverter-Defibrillator: the ChoiCe between the neeD anD 
liMiteD resourCes
Gurtskaya G., Kulkhan T., Sasykova A., Issatayeva N.
Republican Center for Health Development, Astana, Kazakhstan
objeCtives: The severity of the effect in reducing the risk of sudden cardiac 
death has a significant positive impact on the forecast as a whole and significantly 
reduces overall mortality rate among different categories of cardiology patients. 
Meanwhile, it imposes a significant burden on the healthcare budget of the Republic 
of Kazakhstan. Due to the fact that the CD’s implantation is an expensive method 
of treatment, the authors conducted a review of existing studies on the cost-effec-
tiveness of the CD in the application of additional functions - MRI-compatible and 
home monitoring function. Methods: The literature review of the efficacy and 
safety «MRI-compatible CD with home monitoring» were conducted on the database 
of the Cochrane Library, a database of bibliographic review on the effectiveness of 
medical intervention (DARE), database reviews of health technology assessment 
(HTA), PubMED, CADTH, NICE, Clinical Trials and TripDatabase. Results: Search 
results revealed 522 publications, and from this number 3 studies were selected 
for the final analysis. The remaining works were excluded due to non-compliance 
to the PICOS’ criteria. According to the data from representatives Biotronik and 
Medtronic in Kazakhstan the CD’s cost without MRI-compatible, completed with 
electrodes in Kazakhstan ranges $18.000-19.000. ConClusions: Application in 
clinical practice, MRI-compatible CD with home monitoring has significant advan-
tages - the almost complete absence of the risk of adverse events, the possibility 
of more frequent MRI as one of the main methods of diagnosis and early detection 
of various pathological conditions, the avoidance of unnecessary visits to patients 
without necessary evidence, revealing significant changes in the health status of 
patients in the constant monitoring; has a relatively small increase in the cost of a 
complete set of MRI-compatible CD with home monitoring in comparing with the 
cost of a set of CD without this function, an average of 33%.
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Cost-utility of rePetitive transCranial MagnetiC stiMulation 
versus antiDePressant theraPy for treatMent-resistant DePression
Gordon L.G., Nguyen K.
Griffith University, Logan, Australia
objeCtives: Major depressive disorder (MDD) is a debilitating disease that signifi-
cantly decreases quality of life. Repetitive Transcranial Magnetic Stimulation (rTMS) 
therapy is a safe, non-invasive, physical treatment for major depressive disorder. 
We evaluated the cost-effectiveness of rTMS compared with third-line antidepres-
tiveness of 24-hours Holter and up to 30 days ELR, each with different diagnostic 
yield, compliance, and costs in patients with syncope in Colombia. Methods: An 
analytical decision tree model was constructed including diagnostic yield, patient 
compliance, mortality rate, QALYs, associated costs to diagnosis and not having 
a diagnosis. Third party payer perspective, five year horizon and 3.5% discount 
rate for utilities and costs were assumed. Patient pathways and model inputs were 
ascertained from doctor interviews and literature search. Average market prices of 
US$175 for 24-hours Holter and US$627 for ELR were used. Micro-costing for avoided 
emergency visits and hospitalizations was done via Colombian key opinion leader 
interviews and official tariffs for costs of not having a diagnosis along five years. 
Uncertainty adjustments were done when judged appropriate. Incremental Cost 
Effectiveness ratio (ICER) was done, incorporating deterministic and probabilistic 
sensitivity analyses. Results: 24-Holter strategy had 19% diagnosis yield compared 
to 63% for ELR. Over a five year horizon, ELR strategy obtained more QALYs than 
24-Holter (2.62 vs. 2.18), at lower cost, been dominant over 24-hours Holter with 
US$2,165.6 incremental savings per incremental QALY. Sensitivity analysis showed 
the result to be particularly sensitive to disease and untreated syncope utilities 
and cost. The probabilistic sensitivity analysis showed a robust model with 95% 
confidence intervals of 1.83–2.57 QALYs for 24-hours Holter and 2.21–3.04 QALYs 
for ELR. ConClusions: Over a 5 year horizon, the ELR with greater utility (QALY) 
to lower costs, as demonstrated through greater incremental savings per QALY, was 
dominant over 24-Holter. The superior results of the ELR are attributable in part to 
the greater diagnostic yield and higher patient compliance.
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the Cost-effeCtiveness of Drug-eluting stents versus bare Metal 
stents in taiwan
Fang N.1, Yao M.2, Tseng T.1
1Tunghai University, Taichung city, Taiwan, 2National Chiao Tung University, Hsinchu county, 
Taiwan
objeCtives: Drug-eluting stents (DESs) have been shown to reduce in-stent reste-
nosis and target vessel revascularization (TVR) in several large clinical trials. We 
conducted this study to explore the differences in the cost and clinical outcome 
of DESs and bare metal stents (BMSs). Methods: We retrospectively analyzed the 
clinical data and costs of patients with stable angina treated with coronary stents in 
2012 at a medical center in Taiwan. Results: We enrolled 245 patients treated with 
DESs and 194 patients treated with BMSs. The use of DESs is a lower rate of TVR com-
pared with that with BMSs (11% vs. 20%, p = 0.015). Compared with the DES group, 
the overall costs were significantly higher in the BMS group (NT$237727.0±89714.9 
vs. NT$187017.3±129713.5, p < 0.001). ConClusions: The use of DESs reduces the 
rate of TVR at 2 years after intervention, but is probably not cost-effective compared 
with BMSs in patient.
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eConoMiC evaluation of PaClitaxel-eluting balloon Catheter 
for PerCutaneous transluMinal angioPlasty (Pta) in MexiCan 
PoPulation with PeriPheral arterial obstruCtive Disease
Ceballos R.1, Orozco J.J.2, Soto H.3, Carmona M.4, Escobar Juárez Y.4
1Medtronic, Mexico, Mexico, 2Medtronic, Medellin, Colombia, 3Universidad Autonoma 
Metropolitana, México D.F., Mexico, 4HS Estudios Farmacoeconómicos, Mexico City, Mexico
objeCtives: To perform a full economic evaluation through a cost-effectiveness 
analysis of the use of paclitaxel-eluting balloon catheter (IN.PACT™ Admiral) in 
comparison with balloon catheter, for PTA in the treatment of peripheral obstruc-
tive artery diseases in Mexican population, from the perspective the public health 
care system in Mexico. Methods: The measure of effectiveness considered was 
decrease in the rate of target lesion revascularization (TLR). Information about effi-
cacy and safety of the intervention was obtained from a systematic review. Direct 
medical costs were considered (cost of devices as well as the procedure). An incre-
mental cost-effectiveness analysis was performed with a horizon of two years. To 
demonstrate the robustness of the model, univariate sensitivity analysis and proba-
bilistic sensitivity analysis were executed using Monte Carlo simulations. Results: 
Paclitaxel-eluting balloon catheter for PTA (IN.PACT™ Admiral) demonstrated good 
efficacy and safety producing a significant reduction in TLR at six months, which 
was maintained up to 24 months (estimated rate 14.4%), evaluated angiographi-
cally. This was significantly better than that obtained with conventional balloon 
angioplasty (estimated rate 40.3%) in the treatment of restenosis. Total average 
costs were $102,299.00 and $115,652.00 respectively. Therefore the incremental 
cost-effectiveness ratio (ICER) obtained showed that the paclitaxel-eluting balloon 
catheter for PTA (IN.PACT™ Admiral) is a dominant option. Clinical benefits were 
clearly demonstrated by the improvement in the ankle-arm index and Rutherford 
category. ConClusions: Paclitaxel-eluting balloon catheter for PTA (IN.PACT™ 
Admiral) proved to be more effective and less costly than the standard of care in 
the treatment of peripheral obstructive arterial disease, for Mexican public health 
care institutions.
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objeCtives: To develop cost-analysis of MEDIHONEY CALCIUM ALGINATE 
(MEDIHONEY) versus ACQUACEL AG (AG) dressings for chronic-wound treatment in 
adults, from perspective of Brazilian public payers. Methods: Data from Brazilian 
Hospital Information System from October 2013 to September 2014 was used to 
define the annual number of hospital admissions due to chronic wounds (only 
non-surgical records with L97.909 ICD-10 code included). The model assumed that 
patients are discharged at the time their wounds heal. No critically ill patients 
in ICUs were included. Only patients above 20 years old were included. Unit cost 
